ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) will host a live webcast of its fiscal 2013 second-quarter conference call on Wednesday, Jan. 30, 2013, at 3:45 p.m. CT (4:45 p.m. ET). David L. Martin, president and chief executive officer, and Laurence L. Betterley, chief financial officer, will discuss the company’s results for its fiscal second quarter ended Dec. 31, 2012, and its financial outlook. The company will issue a post-market earnings release on Jan. 30.
To access the live webcast, go to the investor section of the company’s website, www.csi360.com, on the day of the conference call and click on the webcast icon. A webcast replay will be available beginning at 5:45 p.m. CT the same day.
To participate in the conference call, dial (888) 680-0860 and enter 21740396. Please dial in at least 10 minutes prior to the call. To pre-register for the call, log on to the following website: https://www.theconferencingservice.com/prereg/key.process?key=PEGHRHLQB. When joining the call, pre-registered participants can enter their PIN code, and other participants can press *0 to reach the operator, or wait on the line for operator assistance.
If you do not have access to the Internet and want to listen to an audio replay of the conference call, dial (888) 286-8010 and enter access number 63349889. The audio replay will be available beginning at 5:45 p.m. CT on Wednesday, Jan. 30, 2013, through 11 p.m. CT on Wednesday, Feb. 6, 2013.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in August 2007. To date, nearly 100,000 of CSI’s devices have been sold to leading institutions across the United States. CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States.
For more information, visit the company’s website at www.csi360.com.